Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Genelux CorporationNASDAQ: GNLX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares dips below year-ago levels

Q1 FY2026 weighted avg shares of 32.5M shares fell 6.9% year over year, behind the +11.4% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 12.6% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.9% toward the trailing-twelve-month pace of +11.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.5M-12.6% QoQ
Last fiscal yearDec 2025
37.18M+18.2% YoY
LTMMar 2026
36.38M+11.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.9%——
1 year+18.2%——
3-year CAGR+14.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
37.18M USD
Year-over-year change
+18.2%
4-year CAGR
+12.0%

Weighted Avg Shares vs competitors

How GNLX compares with its peers on the latest reported figures

  • GNLX's LTM Mar 2026 weighted avg shares of 36.38M shares is the 8th highest of the 11 companies compared; the peer median is 62.84M shares.
  • Its year-over-year change of +11.4% is the 6th highest of 10, against a peer median of +18.4%.
  • Over three fiscal years its annual growth of +14.8% compares with a peer median of +10.6%.
GNLX Competitors Peer median
Weighted Avg Shares for GNLX and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 202684.87M +21.1%+8.2%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
CADLCandel Therapeutics, Inc.LTM Mar 202655.91M +73.2%+22.5%
GNLXGenelux CorporationLTM Mar 202636.38M +11.4%+14.8%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
Peer median (excluding GNLX) 62.84M+18.4%+10.6%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.